CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 935 enrolled
Drug / intervention
Herpes Zoster vaccine GSK 1437173A +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02052596
NCT02052596Phase 3Completed
CompareCT.gov

Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A When Co-administered With Boostrix® in Adults Aged 50 Years and Older

GlaxoSmithKline·interventional·Posted Feb 3, 2014·Updated Apr 24, 2018

In Brief

A Phase 3 clinical trial evaluating Herpes Zoster vaccine GSK 1437173A and Boostrix for Herpes Zoster. Completed, enrolled 935 participants across 13 sites.

Detailed Summary

The purpose of this study is to assess immunogenicity, reactogenicity and safety of GSK Biologicals' HZ/su vaccine when its first dose is co-administered with the Boostrix® vaccine in adults aged 50 years or older compared to administration of vaccines separately.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHerpes Zoster
CountriesUnited States
Collaborators--

Timeline

Phase 3CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedFeb 3, 2014
Enrollment StartFeb 7, 2014
Primary CompletionJun 16, 2015
Study CompletionApr 21, 2016
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 12.4 years ago

Interventions

Herpes Zoster vaccine GSK 1437173Abiological

2 doses administered intramuscularly (IM) in the deltoid region of the non-dominant arm at Visit Day 0 and Visit Month 2 for Co-Ad group and at Visit Month 2 and Visit Month 4 for Control group.

Boostrixbiological

1 dose administered intramuscularly (IM) in the deltoid region of the dominant arm at Visit Day 0 for both Co-Ad and Control groups.